This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Chronic myelogenous leukemia (CML)	Signal transducer and activator of transcription 5 (STAT5)	<p><i>In vitro</i> and cell culture studies suggest that inhibiting STAT5 could help treat CML. In CML cells from patient bone marrow and in imatinib-resistant CML cells, the STAT5 inhibitor pimozone induced cell death compared with vehicle control. Next steps include testing pimozone in animal models of CML.</p> <p>Pimozone, a generic diphenylbutylpiperidine, is approved in the U.S. to treat Tourette syndrome.</p> <p>Gleevec imatinib is marketed by Novartis AG to treat CML and gastrointestinal stromal tumors (GIST).</p> <p>SciBX 4(6); doi:10.1038/scibx.2011.159 Published online Feb. 10, 2011</p>	Patent application filed; available for licensing	<p>Nelson, E.A. <i>et al. Blood</i>; published online Jan 13, 2011; doi:10.1182/blood-2009-11-255232</p> <p>Contact: David A. Frank, Dana-Farber Cancer Institute, Boston, Mass. e-mail: david_frank@dfci.harvard.edu</p>